Atea Pharmaceuticals (AVIR) Competitors $2.95 0.00 (0.00%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. WVE, ETNB, COLL, MLYS, NTLA, SYRE, ZYME, RCUS, NRIX, and CMRXShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Wave Life Sciences (WVE), 89bio (ETNB), Collegium Pharmaceutical (COLL), Mineralys Therapeutics (MLYS), Intellia Therapeutics (NTLA), Spyre Therapeutics (SYRE), Zymeworks (ZYME), Arcus Biosciences (RCUS), Nurix Therapeutics (NRIX), and Chimerix (CMRX). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Wave Life Sciences 89bio Collegium Pharmaceutical Mineralys Therapeutics Intellia Therapeutics Spyre Therapeutics Zymeworks Arcus Biosciences Nurix Therapeutics Chimerix Wave Life Sciences (NASDAQ:WVE) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends. Does the MarketBeat Community prefer WVE or AVIR? Wave Life Sciences received 349 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 67.90% of users gave Wave Life Sciences an outperform vote while only 47.50% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformWave Life SciencesOutperform Votes36867.90% Underperform Votes17432.10% Atea PharmaceuticalsOutperform Votes1947.50% Underperform Votes2152.50% Is WVE or AVIR more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Atea Pharmaceuticals' return on equity of -34.90% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Wave Life Sciences-66.50% -280.57% -52.90% Atea Pharmaceuticals N/A -34.90%-32.38% Do analysts prefer WVE or AVIR? Wave Life Sciences currently has a consensus price target of $21.17, indicating a potential upside of 174.18%. Atea Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 103.39%. Given Wave Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Wave Life Sciences is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals believe in WVE or AVIR? 89.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 29.1% of Wave Life Sciences shares are owned by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor WVE or AVIR? In the previous week, Wave Life Sciences had 5 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 9 mentions for Wave Life Sciences and 4 mentions for Atea Pharmaceuticals. Wave Life Sciences' average media sentiment score of 1.08 beat Atea Pharmaceuticals' score of 1.05 indicating that Wave Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Wave Life Sciences 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, WVE or AVIR? Wave Life Sciences has higher revenue and earnings than Atea Pharmaceuticals. Wave Life Sciences is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWave Life Sciences$108.30M10.94-$57.51M-$0.79-9.77Atea PharmaceuticalsN/AN/A-$135.96M-$2.00-1.48 Which has more risk & volatility, WVE or AVIR? Wave Life Sciences has a beta of -0.93, indicating that its share price is 193% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. SummaryWave Life Sciences beats Atea Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$252.30M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-1.437.4522.4218.48Price / SalesN/A242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book0.446.516.774.25Net Income-$135.96M$143.21M$3.22B$248.23M7 Day Performance3.51%3.97%3.26%3.29%1 Month Performance0.68%0.37%0.02%2.42%1 Year Performance-20.27%2.60%18.01%5.54% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals3.1159 of 5 stars$2.95flat$6.00+103.4%-20.3%$252.30MN/A-1.4370High Trading VolumeWVEWave Life Sciences4.3065 of 5 stars$6.12+3.4%$22.18+262.4%+56.6%$939.33M$108.30M-5.51240Upcoming EarningsAnalyst ForecastPositive NewsETNB89bio3.0075 of 5 stars$6.27+3.5%$27.56+339.5%-5.8%$915.32MN/A-2.1540News CoveragePositive NewsCOLLCollegium Pharmaceutical4.0483 of 5 stars$26.91-0.4%$43.60+62.0%-26.9%$864.67M$631.45M11.60210Upcoming EarningsPositive NewsMLYSMineralys Therapeutics2.3889 of 5 stars$13.24-0.8%$33.00+149.2%+16.0%$858.96MN/A-3.6428Upcoming EarningsShort Interest ↑NTLAIntellia Therapeutics4.4615 of 5 stars$7.92+9.5%$36.68+363.2%-58.6%$819.86M$57.88M-1.46600Upcoming EarningsPositive NewsHigh Trading VolumeSYRESpyre Therapeutics1.7938 of 5 stars$13.57+7.1%$49.57+265.3%-53.9%$817.95M$890,000.00-1.82100Upcoming EarningsPositive NewsZYMEZymeworks2.7679 of 5 stars$11.75+1.9%$21.00+78.7%+51.6%$817.53M$76.30M-7.83460Positive NewsRCUSArcus Biosciences2.0487 of 5 stars$7.68-2.5%$30.25+293.9%-42.6%$807.46M$258M-2.44500Upcoming EarningsPositive NewsGap DownNRIXNurix Therapeutics1.938 of 5 stars$10.55+3.0%$30.44+188.6%-4.1%$804.29M$56.42M-3.65300Analyst ForecastPositive NewsGap DownCMRXChimerix3.0286 of 5 stars$8.55-0.1%$8.53-0.1%N/A$801.56M$212,000.00-9.0990 Related Companies and Tools Related Companies Wave Life Sciences Alternatives 89bio Alternatives Collegium Pharmaceutical Alternatives Mineralys Therapeutics Alternatives Intellia Therapeutics Alternatives Spyre Therapeutics Alternatives Zymeworks Alternatives Arcus Biosciences Alternatives Nurix Therapeutics Alternatives Chimerix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVIR Stock Free AVIR Stock Alerts